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C-myc and Bcl2 are well characterized oncogenes that are capable of forming G-quadruplex structures. Promoter regions of C-
myc and Bcl2 forming G-quadruplex structures are chemically synthesized and G-quadruplex structure is formed in presence of
100mM potassium ion. Three diﬀerent porphyrin drugs, namely TMPyP2, TMPyP3, and TMPyP4 are allowed to interact with
quadruplex DNA complex and the site and nature of interaction are studied. Drug interactions with quadruplex DNA were carried
out in diﬀerent potassium ionic strengths using ﬂuorescence spectroscopy. It is found that ﬂuorescence hypochromicity decreases
with an increase in ionic strength in the case of TMPyP4, TMPyP3, and TMPyP2. Fluorescence titration studies and Job plots
indicate that four molecules of TMPyP4, two molecules of TMPyP3 and TMPyP2 are interacting with one molecule of quadruplex
DNA.
1.Introduction
Bcl2 (B-cell/lymphoma-2) is a proto-oncogene which
encodes for 25KD protein which has a peculiar function of
blocking programmed cell death without aﬀecting prolifera-
tion[1].Thereareabout25genesintheBcl2family.TheBcl2
gene is known to be responsible for a number of cancers like
melanoma, breast, prostate, lung carcinoma, schizophrenia,
and autoimmunity [2] .A ni n c r e a s ei nB c l 2l e v e l si nt h ec e l l
is reported to lead to poor prognosis [3]. Hence control of
the production of Bcl2 in a cell has become a signiﬁcant area
of research. Like Bcl2, C-myc is also an oncogene which has a
G-quadruplex forming sequence in its promoter region. The
protein product of C-myc proto-oncogene controls a variety
of genes that together enhance proliferation of cell [4, 5].
C-myc is overexpressed in many human cancers cells like
leukemia, lung, breast, pancreatic, cervical, etc, [6–8]. The
role of G-quadruplexes in cancer therapeutics is increasing.
Workisunderwayinmanylaboratorieselsewheretoidentify
a suitable synthetic compound or macromolecul, which
can stabilize the quadruplex complex in vivo [9]. Many
synthetic chemicals were tested for their interaction with
quadruplex DNA. Few among them are anthraquinones
[10], acridines [11], perylenes [12], and triazines [13, 14].
Porphyrins are chemical compounds, until that can interact
with quadruplex DNA structure and stabilize them [15, 16].
Today, there has been controversy in the nature and site of
poprhyrin binding to quadruplex DNA structure. Kimura et
al. [17] have studied the interaction between G-quadruplex-
TMPyP4 using 2-aminopurine substituted human telomeric
DNA sequence. Han et al. [18] have demonstrated that
TMPyP4 is a suitable telomerase inhibitor because of its low
toxicity.
Diﬀerent TMPyP4 binding modes to DNA are reported
in the literature, like intercalation between the G-C base
pairs [19, 20], binding to major groove [21] and minor
groove [22, 23], and binding to the DNA surface [24]. Haq
et al. [25] have studied the binding of cationic porphyrin2 Journal of Nucleic Acids
to G-quadruplex DNA using ITC, UV-Vis spectroscopy and
have shown that the stoichiometry of porphyrin binding
to G-quadruplex DNA depends on the number of intervals
between successive G-tetrad planes. Freyer et al. [26]h a v e
recently reported that the binding of TMPyP4 to c-myc NHE
III promoter is in the ratio of 4 : 1, using microcalorimetric
and spectroscopic techniques.
2.MaterialsandMethods
2.1. Oligonucleotide Synthesis. For this study, two diﬀerent
quadruplex forming oncogenic sequences, corresponding to
Bcl2 and C-myc promoter regions were synthesized and
their interactions with three diﬀerent porphyrin drugs were
studied. The sequencesof oligonuclotides usedin the present
study are shown below. The structure of G-quadruplex DNA
and porphyrin drugs is shown in Figure 1. All the structures
shown in Figure 1 are drawn using ACD/ChemSketch (Ver-
sion 12):
27Bcl2-CGGGCGCGGGAGGAAGGGGGCGGG
AGC
C-myc-TGGGGAGGGTGGGGAGGGTGGGGA
AGG
The 27Bcl2 and C-myc oligonucleotide stock solutions
were prepared by dissolving each oligonucleotide into
100mM KBPES buﬀer (0.01M KH2PO4,0 . 0 1 MK 2HPO4,
0.001M EDTA, 0.02–0.6M KCl, KOH added drop wise
to pH 7.0). DNA samples were dialyzed (1000 molecular
weight cutoﬀ membrane) against two changes of buﬀer (1L,
24 hours each) at 4◦C. Concentration of all the oligonu-
cleotides was measured using UV-Vis spectrophotometry
with molar extinction coeﬃcients determined by using
the nearest neighbor calculation for single stranded DNA
[27] and the absorbance of thermally denatured constructs
extrapolated back to 25◦C and/or a total phosphate analysis
technique [28]. The extinction coeﬃcient determined for
two G-quadruplexes by these techniques was C254 =
207840M−1Cm−1 (27Bcl2) and C260 = 215330M−1Cm−1
(c-myc), respectively.
The cationic porphyrins (TMPyP4, TMPyP3, and
TMPyP2) were purchased from Frontier Scientiﬁc (Logan,
Utah, USA). All the porphyrin drugs were used without
further puriﬁcation. The porphyrin solutions were prepared
by dissolution of each drug into a measured volume of
ﬁnal dialysate from the appropriate oligonucleotide solu-
tion preparation as the buﬀer. The concentration of each
porphyrin drug was calculated using the molar extinction
coeﬃcient C424 = 2.26 × 105 M−1Cm−1 [29], C417 = 2.50 ×
105 M−1Cm−1 [30], C414 = 1.82 × 105 M−1Cm−1 [31]f o r
TMPyP4, TMPyP3, and TMPyP2, respectively.
2.2. CD Experimental Studies. Circular dichroism exper-
iments were performed using a JASCO 815 CD spec-
tropolarimeter (Jasco, Tokyo, Japan). The CD spectra were
recorded from 200 to 500nm for characterizing the G-
quadruplex DNA and for studying induced CD by por-
phyrins. For each CD experiment, 5 ×10
−6 M G-quadruplex
DNA was used. CD spectra were recorded using 10×10
−6 M
(1 : 2) and 20 × 10
−6 M( 1:4 )T M P y P 4 .C Dt i t r a t i o n s
were done in 100mM KBPES buﬀer (pH 7.0) at 25◦C.
TMPyP4wasaddedusingacalibratedmicropipette.EachCD
spectrum is recorded three times, and the average of 3 scans
is considered.
2.3.FluorescenceExperiments. Fluorescenceemissionspectra
were measured at 25◦C using a FluoroMax-3 spectroﬂu-
orimeter (Horiba Jobin Yvon, Edison, NJ) using a 1cm
path length quartz cuvette. G-quadruplex DNA samples
were measured in 2mL of 100mM KBPES buﬀer (pH 7.0).
Through out the ﬂuorescence experiment, concentration
of G-quadruplex DNA is kept constant (200nM) and
titrated with increasing concentrations of cationic porphyrin
(0 to 1200nM). Fluorescence spectra were recorded after
each addition of porphyrin to the ﬂuorescent cuvette. G-
quadruplex DNA and porphyrin drug mixture volume
were kept constant throughout the ﬂuorescence titration
(2mL). After each titration, the quartz cuvette was thor-
oughly washed with distilled water and dilute nitric acid
(approximately 0.1N, nitric acid) to remove traces of
porphyrin sticking to the walls of quartz cuvette. TMPyP4,
TMPyP3, and TMPyP2 were excited at 433nm, 417nm,
and 424nm, respectively and emission spectra for each
titration were collected from 600 to 800nm. Each spectrum
was recorded three times and the average of three scans
was taken. The diﬀerence in ﬂuorescence emission maxima
before and after the addition of G-quadruplex DNA was
plotted against concentration of porphyrin to obtain the
porphyrin-G-quadruplex binding curve. In the ﬂuorescence
binding curves (Figure 4), the points of intersection of two
extrapolated lines (initial and ﬁnal), at saturation levels,
will indicate the stoichiometry of G-quadruplex DNA and
porphyrin drugs.
To investigate the eﬀect of ionic strength on ﬂuorescence
hypochromicity (% FH), four diﬀerent KBPES buﬀer solu-
tions (pH 7.0) with increasing concentration of K(I) ion
were prepared. The KBPES (pH 7.0) buﬀer solutions used in
the present study contained 30mM, 100mM, 200mM, and
600mM of potassium ion.
2.4. UV-Vis Spectroscopic Titrations. UV-Vis spectroscopic
titrations were performed using an Agilent 8453 diode array
(Agilent, Santa Clara, CA) at 25◦C using a 1cm path length
quartz cuvette. Stock solutions of 10μMp o r p h y r i na n d
10μM of G-quadruplex DNA were prepared in 100mM
KBPES buﬀer (pH 7.0). Two series of solutions were used for
the experiments. First two mL of dilute G-quadruplex DNA
(10μM) were placed in a 1cm path length quartz cuvette,
and twenty ﬁve × 50μL injections of porphyrin solution
(10μM) were added manually. In the second part, two mL
of dilute cationic porphyrin solution (10μM) were used
and twenty ﬁve × 50μL injections of G-quadruplex DNA
solution were added. Absorption spectra were collected from
350nm to 500nm. The quartz cells were thoroughly cleaned
with distilled water and 0.1N nitric acid to remove traces of
porphyrinthatweredepositedonthewallsofquartzcell.TheJournal of Nucleic Acids 3
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Figure 1: The structures of G-quadruplex DNA and TMPyP2, TMPyP3, and TMPyP4.
diﬀerence in the absorption maxima of the soret band was
plotted versus the prophyrin mole fraction to generate a Job
plot [32–34].
UV-Vis absorption titrations were done by adding G-
quadruplex DNA stock solution (200–350nM) in 100mM
KBPES buﬀer (pH 7.0) to the quartz cuvette containing
approximately 1μM porphyrin solution prepared in the
same buﬀer. G-quadruplex DNA and porphyrin samples
were freshly prepared before performing the experiment. UV
spectra were collectedfrom 200nm to 500nm. The titrations
were carried out until the porphyrin soret band remains
at a ﬁxed wavelength upon ﬁve successive additions of G-
quadruplex DNA.
3. Results andDiscussion
3.1. CD Studies. The CD spectrum (Figure 2(a)) shows a
prominent positive peak at 265nm and a small hump at
295nm, indicating that the 27Bcl2 is forming antiparallel
quadruplex structure in solution. On addition of TMPyP4
(at 1 : 2 and 1 : 4 DNA:TMPyP4 ratio) a weak induced CD
band (ICD) is seen around 435nm, indicating that TMPyP4
is eﬃciently interacting with quadruplex DNA. Whereas
Figure 2(b) demonstrates comparatively weaker interaction
of TMPyP4 with C-myc quadruplex DNA. Furthermore, the
CD spectrum shows a positive peak at 265nm. This indicates
that it is forming parallel quadruplex DNA structure in solu-
tion. When (10×10
−6 M) and (20×10
−6 M) concentrations
ofTMPyP4isaddedto27Bcl2quadruplexDNA(5×10
−6 M),
an e g a t i v ec o t t o ne ﬀect is observed. Small or no cotton eﬀect
is seen, when double and quadruple concentrations of drug
are added to 5 × 10
−6 M, C-myc DNA. A negative cotton
eﬀect in the case of 27Bcl2 is observed due to the diﬀerence
in the conformation of Bcl2 quadruplex DNA. Occurrenceof
induced CD at 435nm and negative cotton eﬀect at 265nm
indicates that Bcl2 quadruplex complex has a marginally
better interaction eﬃciency with TMPyP4.
3.2. UV-Titration Studies. UV-Vis spectroscopy is an excel-
lent technique for ﬁnding the extent of drug interaction with
DNA. In all the drug-DNA interactions, the soret band has
shown a red shift. The soret band has shifted from 423nm
to 441nm (18nm shift) in case of TMPyP4 and the isobestic
point is prominent at 436nm (UV-Vis spectra are similar for4 Journal of Nucleic Acids
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Figure 2: (a) CD spectra for the 27Bcl2 mid promoter sequence, wavelength in nm is plotted on x-axis, and Ellipticity, θ, is plotted on
the y-axis in mdeg. The 5 × 10
−6 M quadruplex DNA is considered for each CD experiment. CD spectra are recorded at 1 : 2 and 1 : 4
quadruplex DNA: TMPyP4 stoichiometry. Each spectrum is recorded thrice, and the average of the three runs is considered. (b) CD spectra
for the C-myc sequence, wavelength in nm is plotted on x-axis and Ellipticity, θ, is plotted on the y-axis in mdeg. The 5×10
−6 M quadruplex
DNA is considered for each CD experiment. CD spectra are recorded at 1 : 2 and 1 : 4 quadruplex DNA: TMPyP4 stoichiometry. Each
spectrum is recorded thrice, and the average of the three runs is considered.
Table 1: UV-Vis absorption titration parameters for TMPyP4, TMPyP3, and TMPyP2 with four diﬀerent Bcl2 and C-myc G-quadruplex
DNA. Soret band hypochromicity is calculated using the formula: % Hypochromicity = [(Cfree − Cbound)/Cfree] × 100. Cfree and Cbound are
the extinction coeﬃcient of free and bound porphyrin, respectively.
S. No. Name of quadrupelx DNA
and cationic porphyrin Soret band shift (nm) Isobestic point (nm) Percentage hypochromicity
1. 27Bcl2-TMPyP4 423–441 435.5 59.7%
2. 27Bcl2-TMPyP3 417–431 426.5 41.5%
3. 27Bcl2-TMPyP2 No shift 422.0 23.0%
4. C-myc-TMPyP4 423–439 432.2 52.3%
5. C-myc-TMPyP3 417–429 425.3 39.5%
6. C-myc-TMPyP2 No shift 421.7 14.7%
both 27Bcl2 and C-myc G-quadruplex sequences). In case of
TMPyP3, the soret band has shifted from 417nm to 431nm
(13-14nm shift) and isobestic point is observed at around
426nm. In the case of TMPyP2 the soret band does not show
a shift from 414nm and an isobestic point is observed at
around 422nm. Percentage of hypochromicity for each G-
quadruplex DNA is calculated by following the procedure
described by Keating and Szalai [32]. The details of UV-Vis
spectral studies are shown in Table 1. Results demonstrate
that both quadruplex DNA’s can interact with TMPyP3
and TMPyP4 drugs. But among them, TMPyP4 interaction
with C-myc and 27Bcl2 quadruplex DNA is more eﬃcient
than TMPyP3. TMPyP2 has very little or no interaction.
Similar observations have been made by Anantha et al.
[35]. They showed that TMPyP4 exhibits both intercalation
and external binding. From UV spectral analysis, it is
evident that the isobestic point when TMPyP4 interacts
with 27Bcl2 quadruplex DNA shows slight deviation at
the end (isobestic point is not a tight single point). This
indicates that interaction involves multiple steps. Where
as with C-myc quadruplex DNA, the isobestic point does
not show any deviation (a tight point is observed). Similar
observations were made while observing the drug-DNA
interaction, ﬂuorimetrically.
3.3. Job Plot. Job plots make it possible to ﬁnd out the
stoichiometry interactions between drugs and quadruplex
DNA. From Figure 3, it is evident that four molecules of
TMPyP4 are interacting with each molecule of C-myc and
27Bcl2 quadruplex DNA. Similar observations have been
made by Freyer et al. [26] only two molecules of TMPyP2
and TMPyP3 are interacting with each quadruplex DNA
complex. The variation in the number of drug molecules
interacting with quadruplex DNA is probably due to the
placement and rotation of methyl groups placed on the
porphyrin molecule. In the case of TMPyP4, the N–CH3
group is in the para position and it has about 360◦
degree of rotation along the axis. Hence the molecules can
attain perfect planar structure when it is interacting with
quadruplexDNA.Duetothisreason,itcanintercalateaswell
as bind externally to quadruplex DNA molecule. In the caseJournal of Nucleic Acids 5
Table 2: Data obtained from Job plot of Bcl2 and C-myc G-quadruplex DNA with TMPyP4, TMPyP3, and TMPyP2 porphyrin drugs.
S. No. Name of gquadrupelx DNA
and porphyrin
Value of mole fraction of
porphyrin matching with
point of intersection
Stoichiometry between
gquadruplex DNA
porphyrin
1. 27Bcl2-TMPyP4 0.78 1 : 3.54
2. 27Bcl2-TMPyP3 0.70 1 : 2.33
3. 27Bcl2-TMPyP2 0.58 1 : 1.38
4. C-myc-TMPyP4 0.76 1 : 3.17
5. C-myc-TMPyP3 0.70 1 : 2.33
6. C-myc-TMPyP2 0.58 1 : 1.38
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Figure 3:Jobplotsforthetitrationofthe27Bcl2midpromoterand
C-myc quadruplex DNA on interaction with TMPyP2, TMPyP3,
and TMPyP4 drugs. Point of intersection of two lines is indicated
by a dashed line.
of TMPyP3 the N-CH3 group is in meta position and it can
have a restricted rotation on its axis. Therefore, this molecule
cannot attain perfect coplanarity, like TMPyP4. Hence it
cannot intercalate completely in between two G-quartets but
prefers to bind externally. With TMPyP2, the N–CH3 groups
are in ortho position. The N–CH3 groups have much more
restricted rotation on its axis, in case of TMPyP2. Hence, the
molecule is incapable of attaining perfect planar structure,
exhibits intercalation with quadruplex DNA and shows only
external binding. Probably due to this reason, TMPyP4 can
intercalate and bind externally, and the drug:quadruplex
DNA stoichiometry is 4 : 1. Where as, TMPyP2 and TMPyP3
prefers to bind externally and the stoichiometry is 2 : 1.
Details were shown in Table 2.
3.4. Fluorescence Hypochromicity. I no r d e rt os t u d yt h ee ﬀect
of buﬀer cationic strength on drug binding to quadruplex
DNA, ﬂuorescence titration was carried out in diﬀerent
KBPS buﬀers with variation in potassium ion concentrations
(30mM,100mM,200mM,and600mM).Resultsemphasize
that ﬂuorescence hypochromicity decreases with increase
of buﬀer salt concentration. It demonstrates that as the
positive ion cloud around quadruplex complex increases, it
occupies the available binding sites on quadruplex complex
surface and reduces the possibility for drug molecules to
bind exterior of quadruplex DNA. A decrease in ﬂuorescence
intensity of the drug may also be due to quenching by the
surroundingwatermolecules.Butifthedrugmoleculeshows
an intercalative mode of binding, quenching of ﬂuorescence
intensity is comparatively less. Because drug molecules are
sandwiched between two G-quartets, the distance between
guanine bases in quadruplex and the drug molecules
becomes less. As the drug molecules come close to guanines
in quadruplex, energy transfer between them takes place,
which results in an increase of ﬂuorescence. An increase
in ﬂuorescence intensity by energy transfer between DNA
bases and the drug molecules, on intercalation, was reported
earlier [36, 37]. The extent of ﬂuorescence attenuation is
not the same with all the three porphyrin drugs. It is
more with TMPyP2, moderate with TMPyP3 and less with
TMPyP4. These results indicate that TMPyP4 can show both
intercalative as well as end binding to quadruplex complex
while TMPyP3, and TMPyP2 prefer to bind externally.
From Tables 3(a) and 3(b) it is evident that percentage of6 Journal of Nucleic Acids
Table 3
(a) Eﬀect of ionic strength on the percentage of ﬂuorescence hypochromicity while 27Bcl2 interacts with porphyrin drugs.
S. No.
Ionic strength of
KBPES buﬀer
(pH7.0)
Stoichiometry
DNA:drug
Percentage of ﬂuorescence
hypochromicity
1. TMPyP4 with 27BCL2
1.a 30mM 1 : 4 34.2%
1.b 100mM 1 : 4 28.5%
1.c 200mM 1 : 4 20.3%
1.d 600mM 1 : 4 6.5%
2. TMPyP3 with 27BCL2
2.a 30mM 1 : 2 59.8%
1 : 3 51.5%
2.b 100mM 1 : 2 52.5%
1 : 3 49.5%
2.c 200mM 1 : 2 33.6%
1 : 3 16.6%
2.d 600mM 1:2 8 . 6 %
1:3 4 . 9 %
3. TMPyP2 with 27BCL2
3.a 30mM 1 : 2 37.4%
1 : 3 40.2%
3.b 100mM 1 : 2 11.9%
1 : 3 12.3%
3.c 200mM 1:2 6 . 5 %
1:3 4 . 4 %
3.d 600mM 1:2 0 . 7 %
1:3 0 . 3 %
(b) Eﬀect of ionic strength on the percentage of ﬂuorescence hypochromicity while C-myc interacts with porphyrin drugs.
S. No.
Ionic strength of
KBPES buﬀer
(pH7.0)
Stoichiometry
DNA:drug
Percentage of ﬂuorescence
hypochromicity
1. TMPyP4 with C-myc
1.a 30mM 1 : 4 39.2%
1.b 100mM 1 : 4 32.6%
1.c 200mM 1 : 4 29.3%
1.d 600mM 1 : 4 5.5%
2. TMPyP3 with C-myc
2.a 30mM 1 : 2 52.8%
1 : 3 49.5%
2.b 100mM 1 : 2 47.5%
1 : 3 42.2%
2.c 200mM 1 : 2 29.6%
1 : 3 12.6%
2.d 600mM 1:2 6 . 6 %
1:3 3 . 9 %
3. TMPyP2 with C-myc
3.a 30mM 1 : 2 42.4%
1 : 3 37.2%Journal of Nucleic Acids 7
(b) Continued.
S. No.
Ionic strength of
KBPES buﬀer
(pH7.0)
Stoichiometry
DNA:drug
Percentage of ﬂuorescence
hypochromicity
3.b 100mM 1 : 2 12.6%
1:3 7 . 2 %
3.c 200mM 1:2 7 . 8 %
1:3 5 . 4 %
3.d 600mM 1:2 0 . 6 %
1:3 0 . 2 %
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Figure 4:Fluorescencetitrationcurves.200nMquadruplexDNAis
titrated with 0–1200nm concentration of three diﬀerent porphyrin
drugs. Stoichiometry is considered at saturation levels. Hence
the slop of initial and end points are considered.1: TMPyP4, 2:
TMPyP3, and 3: TMPyP2.
ﬂuorescence hypochromicity is comparatively higher (from
lower to higher ionic strength), in the case of TMPyP3 and
TMPyP2.Thisindicatesthatdrugmoleculesarequenchedby
thesurroundingwatermolecules.But,inthecaseofTMPyP4,
ﬂuorescence attenuation is gradual. This demonstrates that
though there is quenching of TMPyP4 ﬂuorescence by
surrounding water molecules, there is some increase in the
ﬂuorescence, due to energy transfer between TMPyP4 and
guanines in the quadruplex on drug intercalation. Due to
this, TMPyP4 could exhibit ﬂuorescence even at 600mM salt
concentration. Where as in case of TMPyP2 and TMPyP3
ﬂuorescenceintensityisalmostquenchedbythesurrounding
water molecules, as they are binding externally. The results
obtainedwith27Bcl2aswellasC-mycquadruplexareshown
in Tables 3(a) and 3(b), respectively.
3.5. Fluorescence Titration. In this study, 200nM of G-
quadruplex DNA was considered for interaction with three
diﬀerent porphyrin drugs in the range of 0–1200nM. From
Figure 4 it is evident that the binding curve has multiple
inﬂection points. 27Bcl2 shows a comparatively higher
number of inﬂection points, indicating that the interaction
occurs in multiple steps. Since it is intended to know the sto-
ichiometry at saturation levels, only slopes of initial and ﬁnal
titrations are considered. The titration demonstrates that
with one molecule of G-quadruplex DNA, four molecules
of TMPyP4 and two molecules of TMPyP2 and TMPyP3
are interacting. It is also clear that the saturation point
is occurring relatively at lower concentration in case of
TMPyP2 (as the slope of binding curve is steep), moderate
in TMPyP3, and at higher concentration in TMPyP4. The
reason for diﬀerence in the nature of interaction of three
porphyrins with quadruplex DNA is probably due to the
orientation of N-CH3 groups on the drug molecule and the
nature of binding.
4. Conclusions
Fromthepresentstudy,itcanbeconcludedthatcationicpor-
phyrins show diﬀerent modes of binding to G-quadruplex
DNA. The nature of binding depends upon the position of
the bulky N+-CH3 groups on porphyrin. Experiments with
CD, ﬂuorescence, and UV-Vis spectroscopic techniques indi-
cate that TMPyP4 can bind externally as well as intercalate
between the two G-tetrads. Two porphyrins, TMPyP3 and
TMPyP2, prefer external binding to G-quadruplex DNA.
Job plots and ﬂuorescence binding curves indicate that four
molecules of TMPyP4 and two molecules of TMPyP2 and
TMPyP3 interact with 27Bcl2/C-myc G-quadruplex DNA.
As the ionic strength of the buﬀer increases, ﬂuorescence8 Journal of Nucleic Acids
hypochromicity decreases. The extent of reduction in ﬂuo-
rescence hypochromicity is high in TMPyP2 and TMPyP3,
and moderate in the case of TMPyP4. The variation in ﬂuo-
rescence hypochromicity is probably due to the diﬀerence in
the mode of drug interaction with quadruplex DNA.
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